Pfizer/AstraZeneca: Battleground Shifts To U.K. Parliament
This article was originally published in The Pink Sheet Daily
Executive Summary
Pfizer CEO Read tried to assure U.K. legislators that an acquisition of the country’s second-largest drug company would not stunt pharma R&D in Britain at a May 13hearing. AstraZeneca CEO Soriot countered that the company’s pipeline will progress quicker if the company remains independent, resulting in future benefits to the U.K.